Whether inhibition of MIF or oxMIF may offer promising therapies in clinical conditions, such as AKI, CKD, diabetic nephropathy, inflammatory kidney diseases, and ADPKD, needs to be elaborated in future interventional studies. The gene discussed is MIF; the disease is autosomal dominant polycystic kidney disease.